Coronavirus vaccine: Russia will supply its drug against covid-19 to Colombia and other countries – Health



[ad_1]


Russia will supply its covid-19 drug, registered under the name Afivavir, to 17 other countries, including Argentina, Brazil, Chile, Colombia and more from Latin Americathe authorities reported Thursday.

(Also read: Putin offers the Russian vaccine against covid-19 to the UN for free)

The Fund for Direct Investments of Russia (FIDR) indicated in a statement that the first antiviral against the coronavirus registered in Russia will also be exported to El Salvador, Honduras, Panama, Paraguay and Uruguay.

In addition, the drug, which is already available in medical centers in Russia, will be shipped to Saudi Arabia, Serbia, the United Arab Emirates and South Africa.

(You may be interested: Covid-19: side effects revealed in volunteers of the Russian vaccine)

Previously, Afivavir has already been supplied to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan.

The authorities await the arrival of Afivavir to Russian pharmacies in October this year. The price of the medicine will be approximately 8,000 rubles (about 400,000 Colombian pesos), according to the Russian media.

The Russian Ministry of Health registered Afivavir on May 31. It was the first antiviral drug in that country to treat COVID-19 and showed great efficacy during clinical trials.

(Also: The Colombian doctor working on a Russian vaccine trial against covid)

Russia registered another 6,595 cases of covid-19 and 149 deaths from this disease on Monday. Moscow, the epicenter of the infection in this country, added 1,050 new cases of coronavirus on Thursday, the highest number of infections in the last three months.

In total, the number of confirmed cases of coronavirus in the country amounts to 1’128,836, which places Russia in fourth place in the world by number of confirmed cases of covid-19, after the US, Brazil and India.

(We recommend you read: Alert for scams with fake Russian vaccine against covid-19)

EFE

[ad_2]